<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006200</url>
  </required_header>
  <id_info>
    <org_study_id>NCRR-M01RR00096-1000</org_study_id>
    <secondary_id>M01RR000096</secondary_id>
    <nct_id>NCT00006200</nct_id>
  </id_info>
  <brief_title>Thalidomide and Dacarbazine for Metastatic Melanoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to assess the activity of thalidomide in combination&#xD;
      with dacarbazine (DTIC) in patients with metastatic melanoma. Safety and toxicity of the two&#xD;
      drugs will also be assessed. Dacarbazine is the standard medical treatment for metastatic&#xD;
      melanoma. It has been shown to produce tumor shrinkage in approximately 20% of patients with&#xD;
      advanced melanoma. This shrinkage is usually incomplete and lasts a short time. Thalidomide&#xD;
      is a drug that inhibits tumor blood vessel growth. It can be given orally. It is hoped that&#xD;
      this combination can be given to patients with metastatic melanoma without causing too much&#xD;
      toxicity while increasing the response rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with metastatic melanoma.&#xD;
&#xD;
          -  Lesions must be measurable.&#xD;
&#xD;
          -  Patient must have the following minimum labs: ANC&gt; 1500/mm3, Hemoglobin &gt; 8 mg/dl;&#xD;
             platelets &gt; 100,000 mm3; and liver function tests &lt; 5x normal; and creatinine &lt; 1.5&#xD;
             mg/dl.&#xD;
&#xD;
          -  ECOG performance status &gt; 2.&#xD;
&#xD;
          -  No prior therapy with DTIC or thalidomide&#xD;
&#xD;
          -  No other history of malignancy other than curatively resected basal cell carcinoma of&#xD;
             the skin or carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Patients must not be pregnant or lactating.&#xD;
&#xD;
          -  Sexually active men and women of childbearing age must use adequate contraception. All&#xD;
             patients must understand the potential for severe birth defects with thalidomide and&#xD;
             must be able to follow instructions to avoid conception while taking thalidomide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2004</verification_date>
  <study_first_submitted>September 9, 2000</study_first_submitted>
  <study_first_submitted_qc>September 9, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

